| Audience | Veterans with chronic low back pain, pain clinicians, primary-care clinicians, rehabilitation clinicians, and cannabis-medicine professionals |
| Primary Topic | Dronabinol phase IIa trial protocol for chronic low back pain in Veterans |
| Source | Read the full study |
Dronabinol for Chronic Low Back Pain: What the Veterans Trial Will Actually Test
The planned trial will randomize 75 Veterans with chronic low back pain to oral dronabinol or placebo. Its main purpose is safety and tolerability, with pain and function outcomes treated as exploratory signals for future research.
| Study Type | Published clinical trial protocol |
| Trial Design | Phase IIa, single-site, randomized, double-blind, placebo-controlled, parallel-group trial |
| Population | Veterans with chronic low back pain |
| Planned Sample Size | 75 participants |
| Randomization | 2:1 allocation to oral dronabinol or matching placebo |
| Treatment Duration | 8 weeks after a screening period of up to 4 weeks |
| Primary Objective | Evaluate safety and tolerability |
| Primary Outcomes | Treatment-emergent adverse events, serious adverse events, laboratory findings, vital signs, and electrocardiogram results |
| Exploratory Outcomes | Pain intensity, physical function, emotional function, global improvement, analgesic use, and adherence |
| Clinical Trial ID | NCT06454669 |
| Journal | Pain Management |
| Published | June 10, 2026 |
| PMID | 42267534 |
| DOI | 10.1080/17581869.2026.2685608 |
Dronabinol is a prescription synthetic form of THC. The trial will compare oral dronabinol with matching placebo in Veterans with chronic low back pain.
Participants will be randomized in a 2:1 ratio, meaning more participants will receive dronabinol than placebo. The treatment period is planned for 8 weeks.
The protocol identifies safety and tolerability as the primary objective. That is appropriate because THC-based medicines can cause dizziness, sedation, cognitive effects, mood effects, and cardiovascular or medication-related concerns.
The trial will monitor treatment-emergent adverse events, serious adverse events, labs, vital signs, and ECG findings. Pain outcomes are included, but they are exploratory.
The paper does not report trial results. It cannot show that dronabinol reduces back pain, improves function, lowers opioid use, or outperforms existing treatments.
The authors state that the study is designed to generate safety data and preliminary effect-size estimates for a future confirmatory trial. That is different from proving efficacy now.
Veterans experience chronic pain at high rates and may have overlapping sleep, mood, trauma, mobility, and medication issues. A trial in this population can be clinically meaningful if interpreted carefully.
At the same time, results from one single-site Veteran trial may not automatically generalize to all patients with low back pain.
Cannabinoid pain research often suffers from mixed products, small trials, and unclear endpoints. This protocol is useful because it defines a product and separates safety outcomes from exploratory efficacy outcomes.
If completed, the study may help determine whether a larger trial is worth doing. That is a valuable step, even before it changes clinical practice.
This is exactly the kind of study design cannabis medicine needs: defined product, defined population, placebo control, blinding, and explicit safety outcomes.
But protocol publication is not proof. Patients should not hear ‘dronabinol trial’ and assume ‘dronabinol works.’ We should wait for data and keep the outcome hierarchy clear.
Why a Trial Protocol Is Not a Treatment Result
Trial protocols matter because they show what researchers plan to test and how carefully they plan to test it. But they do not contain the outcome data patients and clinicians need for treatment decisions.
This distinction is especially important in cannabis medicine, where interest can move faster than evidence.
How to Read a Protocol Responsibly
Design
Randomization, blinding, and placebo control make the planned trial stronger than uncontrolled reports.
Primary Outcome
Safety and tolerability are primary, so efficacy claims should wait.
Exploratory Signals
Pain and function measures may guide future trials, but this study is not powered to prove them.
Clinical Translation
Treatment decisions should wait for results, replication, and patient-specific risk review.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, and critics can read the same data differently. These evidence-based lenses show where this trial is useful, where it remains uncertain, and how easily it can be overstated.
This Is Not Yet a Reason to Start Dronabinol
The study has not reported results. It does not show that dronabinol improves chronic low back pain.
It does show that researchers are testing the question in a more rigorous way.
The Endpoint Hierarchy Matters
Safety and tolerability are primary. Pain and function outcomes are exploratory.
That distinction should shape how clinicians talk about the trial with patients.
No Outcome Data Yet
A skeptic will note that protocols can be well designed and still produce negative, inconclusive, or safety-limited results.
The right response is patience.
Sample Size and Generalizability
Seventy-five participants can help estimate safety and variance, but it is not a definitive efficacy sample.
A single-site Veteran trial may not generalize to all chronic low back pain populations.
A Needed Move Toward Product-Specific Testing
Cannabinoid pain studies often mix products and populations. This protocol tests a defined prescription THC product.
That makes future interpretation cleaner if the study is completed.
THC Safety Is Central
Dronabinol can cause sedation, dizziness, cognitive effects, anxiety, and other adverse effects.
Veterans may also have complex medication lists and comorbidities, making safety monitoring essential.
What Results Should Tell Us
The most useful results will clarify tolerability, adverse effects, adherence, and whether pain/function signals justify a larger trial.
A future confirmatory study would need adequate power for efficacy.
Non-Opioid Options Need Real Evidence
The need for non-opioid pain options is real, but policy and practice should not shortcut the evidence process.
Rigorous THC trials are welcome, but claims should follow results.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Have thoughts on this? Share it:
Frequently Asked Questions
Did this paper show that dronabinol works for chronic low back pain?
No. It is a protocol describing a planned trial. It does not report efficacy results.
What is dronabinol?
Dronabinol is a prescription synthetic form of THC.
Who will be studied?
The planned trial will enroll Veterans with chronic low back pain.
How many participants are planned?
Seventy-five participants are planned, randomized two to one to dronabinol or placebo.
What is the primary objective?
The primary objective is to evaluate safety and tolerability.
Will the trial measure pain?
Yes, pain intensity and other clinical outcomes are exploratory secondary measures.
Is the study powered to prove efficacy?
No. The protocol says it is not powered to test efficacy hypotheses.
Why is placebo control important?
Placebo control helps separate treatment effects from expectation, time, and other changes.
Should patients seek dronabinol because of this protocol?
No. Treatment decisions should wait for data and should be made with a clinician.
What is the main takeaway?
The trial is worth watching because it is rigorous, but it does not yet answer whether dronabinol helps chronic low back pain.
